← Back to Search

Pioglitazone 30 mg for Insulin Resistance

Phase 2
Waitlist Available
Research Sponsored by St. Louis University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months

Summary

This trial tests pioglitazone, a drug that helps control blood sugar, in men with prostate cancer who are on a treatment that often causes insulin resistance. The goal is to see if pioglitazone can reduce this side effect. Pioglitazone is a medication that improves insulin sensitivity and has been used to treat type 2 diabetes by lowering blood glucose levels and improving lipid profiles.

Eligible Conditions
  • Insulin Resistance
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
insulin sensitivity
Secondary study objectives
Insulin signaling (Insulin receptor substrate expression in fat tissue)

Side effects data

From 2013 Phase 3 trial • 936 Patients • NCT01183013
8%
Oedema peripheral
7%
Nasopharyngitis
7%
Hyperglycaemia
5%
Urinary tract infection
5%
Headache
5%
Dizziness
4%
Upper respiratory tract infection
4%
Arthralgia
4%
Back pain
4%
Pain in extremity
3%
Bronchitis
3%
Hypertension
1%
Retinal artery embolism
1%
Myocardial infarction
1%
Constipation
1%
Congestive cardiomyopathy
1%
Gastrointestinal haemorrhage
1%
Appendicitis
1%
Basal cell carcinoma
1%
Renal cell carcinoma
1%
Sleep apnoea syndrome
1%
Oedema
1%
Acute myocardial infarction
100%
80%
60%
40%
20%
0%
Study treatment Arm
Pio30/Pio30
Lina5Pio45/Lina5Pio45
Lina5/Lina5
Pio15/Pio30
Pio45/Pio45
Lina5Pio15/Lina5Pio30
Lina5Pio30/Lina5Pio30

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: PioglitazoneExperimental Treatment1 Intervention
Group II: placeboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pioglitazone 30 mg
2021
Completed Phase 4
~1770

Find a Location

Who is running the clinical trial?

St. Louis UniversityLead Sponsor
194 Previous Clinical Trials
41,023 Total Patients Enrolled
1 Trials studying Insulin Resistance
~0 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top